Welcome to our dedicated page for abrdn Life Sciences Investors SEC filings (Ticker: HQL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the real story inside a closed-end fund’s disclosures can feel like navigating biotech research itself. abrdn Life Sciences Investors’ filings span traditional corporate forms and fund-specific reports, mixing 10-K narratives with N-CSR portfolio tables and Form 4 insider trades linked to FDA catalysts. If you are searching for “abrdn Life Sciences Investors SEC filings explained simply”, you are in the right place.
Stock Titan’s AI breaks down each document—whether it’s an annual report 10-K simplified, a quarterly earnings report 10-Q filing, or an 8-K material events explained—and highlights what matters: shifts in biotech allocations, NAV premium or discount trends, dividend policy changes, and risk updates on clinical pipelines. Our engine also flags “abrdn Life Sciences Investors insider trading Form 4 transactions” in real time, so you can monitor executive stock transactions before they hit your portfolio model.
Every filing arrives within minutes of EDGAR publication and is paired with:
- AI-powered summaries that translate dense accounting notes into clear talking points
- Keyword search to track executive compensation in the proxy statement
- Side-by-side comparisons for quarter-over-quarter portfolio changes
- Instant alerts on “abrdn Life Sciences Investors Form 4 insider transactions real-time”
Whether you want a concise earnings report filing analysis, need to understand reserve levels for biotech follow-ons, or simply prefer “understanding abrdn Life Sciences Investors SEC documents with AI”, this page delivers the insight required to make informed decisions—without sifting through hundreds of pages.
Saba Capital and affiliated persons report beneficial ownership of 2,586,652 common shares of abrdn Life Sciences Investors, representing 8.96% of the outstanding class based on 28,872,416 shares. The filing amends prior Schedule 13D disclosures and states acquisition funds came from investor subscriptions, capital appreciation and margin borrowings, with approximately $33,922,037 paid for the shares. The reporting group consists of Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein. The positions reported are held with shared voting and dispositive power and the advised funds retain rights to dividends and sale proceeds. Transactions executed in the open market since the prior filing are noted and incorporated by reference.
Saba Capital Management, L.P. reported insider sales of abrdn Life Sciences Investors (HQL) common stock on a Form 4. The filing lists two dispositions: 6,989 shares sold on 09/19/2025 at $14.10 and 41,623 shares sold on 09/22/2025 at $14.14. After the reported transactions, Saba Capital’s beneficial ownership is shown as 2,837,633 shares (indirect), down from 2,879,256 shares following the earlier sale. The Form identifies the reporting entity as Saba Capital Management, L.P., with signatures dated 09/23/2025.
Saba Capital Management, L.P. reported two insider sales of abrdn Life Sciences Investors (HQL) common stock. On 09/17/2025 the filer sold 24,328 shares at $13.99, leaving 2,926,453 shares beneficially owned indirectly. On 09/18/2025 the filer sold 40,208 shares at $14.07, leaving 2,886,245 shares beneficially owned indirectly.
The Form 4 is signed by representatives of Saba Capital (Zachary Gindes and Boaz Weinstein) on 09/19/2025. The filing identifies the reporting person as a Director and reports indirect beneficial ownership of the disclosed shares.
Saba Capital Management, L.P. reported insider sales of 700 shares of abrdn Life Sciences Investors (HQL) on 09/15/2025 at $14.13 and 2,026 shares on 09/16/2025 at $13.99. After these transactions the filer beneficially owned 2,950,781 shares indirectly. The filing lists the reporting relationship as a Director and is signed by Zachary Gindes and Boaz Weinstein on 09/17/2025. No derivative transactions were reported.
Saba Capital Management, L.P. reported a Form 4 showing an insider sale of 15,116 shares of abrdn Life Sciences Investors (HQL) on 09/11/2025 at a price of $14.28 per share. After the transaction, the reporting person beneficially owned 2,953,507 shares indirectly. The filing reflects compliance with Section 16 reporting for a director-level reporting person.
abrdn Life Sciences Investors (HQL) insiders reported an indirect sale of common stock. On 09/02/2025 Saba Capital Management, L.P. and Boaz Weinstein reported a disposition of 14,083 shares at $14.04 per share. After the sale, the reporting persons beneficially owned 2,968,623 shares indirectly. The Form 4 was filed by more than one reporting person and signed on 09/04/2025.
Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein jointly report beneficial ownership of 2,982,706 common shares of abrdn Life Sciences Investors (ticker HQL), representing 10.33% of the outstanding common shares based on 28,872,416 shares as of March 31, 2025. The Reporting Persons state approximately $39,115,994 was paid to acquire these shares, funded from investor subscriptions, capital appreciation and margin borrowings. The filing is Amendment No. 7 to a Schedule 13D/A and updates Items 3, 5 and 7; the Reporting Persons assert no specific purpose for the holdings and indicate dividends and sale proceeds flow to the advised funds.
Saba Capital Management and individual reporting person Boaz Weinstein disclosed an insider sale in abrdn Life Sciences Investors (HQL). On 08/29/2025 they sold 23,723 shares of common stock at an average price of $13.89 per share. After the transaction, the reporting persons beneficially owned 2,982,706 shares indirectly. The Form 4 identifies the reporting persons as a director and a 10% owner and is signed on 09/02/2025.
Saba Capital Management, L.P. and individual reporting person Boaz Weinstein disclosed a small insider sale of abrdn Life Sciences Investors (HQL) common stock. On 08/26/2025 400 shares were sold at $13.83 per share. After the transaction the reporting entities beneficially owned 3,006,429 shares on an indirect basis. The filing identifies the reporters as a director and 10% owner.
abrdn Life Sciences Investors (HQL) insiders Saba Capital Management, L.P. and Boaz Weinstein reported a sale of common stock on 08/21/2025. The filing shows a disposition of 10,710 shares at a price of $14.07 per share. After the reported transaction, the reporting persons beneficially own 3,006,829 shares indirectly. The Form 4 is signed and dated 08/25/2025 and was filed as a joint report by more than one reporting person. No derivative transactions were reported in this filing.
FAQ
What is the current stock price of abrdn Life Sciences Investors (HQL)?
What is the market cap of abrdn Life Sciences Investors (HQL)?
